



20th KM Hosur Road, Electronics City, Bangalore 560 100

Bangalore, April 15, 2015

Biocon's Q4 & Full Year FY 2015 Results Conference Call

At 3.30 pm IST on April 30, 2015

Biocon Limited (BSE code: 532523, NSE Id: BIOCON) will announce results for the fourth quarter and full year ended March 31, 2015 after the Board meeting on April 29, 2015. Following the announcement, the management of Biocon Limited will host an earnings call to discuss the Company's financial performance as per the details below.

| | |
|--|--|
| Date: | April 30, 2015 |
| Time: | 3:30 pm IST |
| Dial-in Numbers: | |
| Primary Number Secondary Number | +91 22 3938 1081 +91 22 6746 5891 |
| Local Access Number | 6000 1221 (Ahmedabad, Bangalore, Bhubaneswar, Chandigarh, Chennai, Coimbatore, Delhi, Goa, Guntur, Gurgaon, Hyderabad, Indore, Jamshedpur, Kanpur, Kochi/Cochin, Kolhapur, Kolkata, Nagpur, Noida, Patna, Pune, Raipur, Rajkot, Surat, Trivandrum, Vadodara, Vijayawada. Accessible from all major carriers except BSNL/MTNL.) 3940 3977 (Available in - Ahmedabad, Bangalore, Chandigarh, Chennai, Gurgaon (NCR), Hyderabad, Kochi/Cochin, Kolkata, Lucknow, Pune. Accessible from all carriers) |
| International Toll Free Numbers | USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 |
| Pre-Registration Facility (Special Facility where you can pre-register for the call, and then directly dial-in on the day of the call, without waiting for the operator. You will also get reminders to attend the investor call.) | <ul style="list-style-type: none">• Step 1: Pre-register here. You will receive a passcode and a pin for the call on the registered email address• Step 2: Dial into the call on the Conference Call date, enter the passcode & pin as prompted.• Step 3: You are directly connected to the call |
| Replay Facility | The replay will be available after the earnings call ends. Replay available till May 07, 2015. Dial in number: +91 22 6181 3322 Playback ID: 311121 |

Transcript

The transcript of the earnings call will also be available on the Company's website (www.biocon.com) approximately seven working days post the earnings call.

About Biocon

Biocon Limited, publically listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global biopharmaceutical enterprise serving customers in over 85 countries, it is committed to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through innovative products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. It has successfully developed and taken a range of novel biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin and analogs from 'Lab to Market'. Some of its key brands are INSUGEN® (rh-insulin), BASALOG® (Glargine), CANMAb™ (Trastuzumab), BIOMAb-EGFR™ (Nimotuzumab) and ALZUMAb™ (Itolizumab), a 'first in class' anti-CD6 monoclonal antibody. It has a rich pipeline of biosimilars and novel biologics at various stages of development including a high potential oral insulin. Visit: www.biocon.com

Contact:

For further information please contact:

Saurabh Paliwal

Investor Relations – Biocon Limited
Email: saurabh.paliwal@biocon.com
Tel: +91 80 6775 2040

Diwakar Pingle

Christensen Investor Relations
Email: dpingle@ChristensenIR.com
Tel: +91 22 4215 0210

Disclaimer: *Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. There can be no assurance that future developments affecting Biocon and its subsidiaries / associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Biocon does not intend, and is under no obligation, to update any particular forward-looking statement made at the conference call.*